Objective To explore the clinical effect and safety of gammaglobulin combined with tacrolimus in the treatment of myasthenia gravis（MG）.Methods Eighty cases of MG patients treated in a hospital in Fuxin city from December 2019 to December 2020 were selected for the stud and divided into a study group and a control group using the computerized random grouping method

with 40 cases in each group.The patients in the control group were treated with tacrolimus

and the patients in the study group were treated with gammaglobulin on top of the control group

and both groups were treated for 30 d.The incidence of adverse reactions in the two groups was compared

and the quantitative myasthenia gravis（QMG） test scores

changes in immunobiochemical indexes [tumor necrosis factor-α（TNF-α）

estradiol（E

2

）] levels before and after treatment were compared between the two groups.Results Before treatment

there was no statistically significant difference in QMG score

TNF-α and E

2

levels between the 2 groups（P

>

0.05）.After treatment

the QMG scores

TNF-α and E

2

levels were lower in both groups than before treatment

lower in the study group than in the control group

and the differences were statistically significant（P

<

0.001）.The incidence of adverse reactions in patients in the study group was 10.00%

which was higher than that in the control group（7.50%）

but the difference was not statistically significant（P

>

0.05）.Conclusion Gammaglobulin combined with tacrolimus therapy can significantly improve the severity of myasthenia gravis and immune function in MG patients with a high safety profile

and it may be further promoted.